Comparison · NCT00530218-deaths
Patients With CMV Reactivation Detected vs Patients Without CMV Reactivation Detected: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Patients With CMV Reactivation Detected vs Patients Without CMV Reactivation Detected: deaths from any cause. Trial comparisons, record NCT00530218-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00530218-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.528 | 0.37 | 0.68 | wilson | |
| Risk in group 2 | 0.56 | 0.371 | 0.733 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0322 | -0.267 | 0.211 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.942 | 0.592 | 1.5 | log | |
| Odds ratio, group 1 over group 2 | 0.878 | 0.315 | 2.45 | log | |
| Number needed to treat, for one fewer death from any cause on Patients With CMV Reactivation Detected than on Patients Without CMV Reactivation Detected | 31 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Patients With CMV Reactivation Detected | CMV Positive Blood Culture at Day 21 or later -or- CMV Positive PCR Test at Day 21 or later | 19 | 36 | EG000 |
| Group 2 | Patients Without CMV Reactivation Detected | No CMV Positive Blood Culture at Day 21 or later -and- No CMV Positive PCR Test at Day 21 or later | 14 | 25 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Death was monitored from Day 0 up to Year 11. Serious and other adverse events were assessed from Day 21 up to Day 100.
Source ClinicalTrials.gov
Trial
- Title
- Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
- NCT number
- NCT00530218
- Phases
- PHASE2
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Leukemia, Lymphoma, Multiple Myeloma, MDS, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- Ganciclovir
- Lead sponsor
- City of Hope Medical Center
- Results first posted
- 2017-12-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00530218?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00530218-deaths